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Abstract
Background: Extracorporeal life support systems are well-established devices for treating patients with acute cardiopulmonary
failure. Severe or morbid obesity may result in complications such as limb ischemia, bleeding, unsuccessful cannulation, or
infection at the cannulation sites. This article reports on our experience with cannulation and associated complications in severely
and morbidly obese patients. Methods: Between January 2006 and September 2016, 153 severely or morbidly obese patients
with a body mass index >35 kg/m2 were cannulated percutaneously for extracorporeal life support at our center. Among those,
115 patients were treated with venovenous extracorporeal membrane oxygenation (VV ECMO) for acute lung failure and 38
patients with venoarterial extracorporeal membrane oxygenation (VA ECMO) for cardiogenic shock. Complications related to
percutaneous access and long-term follow-up were analyzed retrospectively. Primary focus was on the success of cannulation,
outcome, thrombosis, bleeding, limb ischemia, and infection at the cannulation site. Normal-weight patients receiving extra-
corporeal life support served as control. Results: Percutaneous cannulation was successfully performed in all patients. Eighty-five
(74%) patients were weaned from VV ECMO and 20 (52%) patients were weaned from VA ECMO. Limb ischemia requiring
surgical intervention occurred in 5 (3%) patients, bleeding in 7 (5%) patients, and wound infection in 3 (2%) patients. In all other
patients, decannulation was uneventful. These data as well as the long-term survival rates were comparable to those of normal-
weight patients (P > .05). Conclusion: Percutaneous vessel cannulation for extracorporeal life support systems is generally
feasible. Therefore, percutaneous cannulation may well be performed in severely and morbidly obese patients. Patient outcome
rather depends on appropriate support than on anatomy.
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Background
Extracorporeal life support systems are well-established
devices for treating patients with acute cardiopulmonary failure
in specialized facilities.1 Improvements in cannulation tech-
niques and support devices enable the initiation of extracorpor-
eal cardiorespiratory support virtually everywhere. The devices
are implantable even far from cardiosurgical units in emer-
gency departments or nonsurgical intensive care wards and as
part of rescue conditions outside hospitals. The indications for
venovenous, venoarterial, or pumpless extracorporeal assists
are well defined and are subject to recommendations of the
Extracorporeal Life-Support Organization.
Patient survival depends on the selection of the appropriate
support device and its management.1,2 Severe obesity is often con-
sidered a contraindication to extracorporeal life support because of
the considerable technical challenge during percutaneous cannula-
tion.3 Apart from the most frequent complications, leg ischemia
and bleeding, the most feared complications are unsuccessful can-
nulation and infections at the cannulation site.2 The article reports
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on our experience with percutaneous cannulation for extracorpor-
eal life support systems and associated complications in severely
and morbidly obese patients without prior cardiac surgery.
Methods
Study Population
Between January 2006 and September 2016, 1168 extracorporeal
life support systems were implanted. All data were prospectively
saved in a database on an access-controlled personal computer.
Patients who had undergone cardiac surgery prior to extracorpor-
eal life supportwere excluded.A surgically implanted cannula for
extracorporeal support was also considered an exclusion criter-
ion. The patients were retrospectively analyzed according to the
extracorporeal support required. Severe obesity was defined as a
bodymass index (BMI) of >35 kg/m2 according toWorld Health
Organization definition (Figure 1).
Cannulation
Prior to cannulation, the access vessels were evaluated by
means of duplex ultrasound, unless resuscitation was ongoing.
After puncture of the vessel and insertion of a guidewire, a dose
of 5000 IU of heparin was injected. The vascular access was
gradually dilated (Percutaneous Insertion Kit; Maquet Cardio-
pulmonary AG, Rastatt, Germany) up to the size of the chosen
cannula, facilitating cannula placement. Special equipment
may be required for percutaneous implantation such as special
guidewires (ie Amplatz Super Stiff, Boston Scientific, Massa-
chusetts). Arterial cannulas sized 15F or 17F (length 23 cm)
were inserted, and venous cannulation was performed with
cannulas of 21F (length 38 cm). Distal leg perfusion has been
used as a standard procedure since 2014.
For the cannulation using a dual lumen cannula (Avalon
cannula; Maquet Cardiopulmonary AG, Rastatt, Germany),
duplex sonography of the right jugular vein was deemed man-
datory for choosing the correct anatomic localization and size
and for excluding thrombotic occlusion. The cannula was per-
cutaneously implanted according to the Seldinger technique,
generally supported by transesophageal echocardiography and,
in rare cases, by fluoroscopy. Cannulation of the subclavian
vein as a return vessel access (size 15F-17F) for venovenous
extracorporeal membrane oxygenation (VV ECMO) was also
supported by transesophageal echocardiography.
Figure 1. Patient selection diagram. BMI indicates body mass index; VA ECMO, venoarterial extracorporeal life-support; VV ECMO, veno-
venous extracorporeal life-support.
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Support and Complications
On ECMO support, partial thromboplastin time (PTT) and
antithrombin III (AT III) were monitored to ensure appropriate
anticoagulation with heparin. If necessary, AT III was substi-
tuted to achieve a target value of 50%. Administration of
heparin was stopped 2 hours prior to decannulation. In general,
decannulation was conducted by simply pulling out the can-
nula. The arterial cannula was removed first to maintain the
possibility of infusing the volume via the venous cannula. After
manual compression of the arterial puncture site, compression
was continued by applying a Safeguard system (Pressure
Assisted Device; Maquet Cardiopulmonary AG, Rastatt, Ger-
many) for 24 hours.
Weaning and survival were analyzed as well as the type and
incidence of complications related to the percutaneous access
to femoral vessels and the jugular or subclavian vein. Implan-
tations performed outside our center were also considered. The
primary end point was on the success of cannulation. Bleeding
at the cannulation site was defined by the requirement of the
transfusion of packed red blood cells, the hemoglobin target for
transfusion being 9 g/dL at our institution. Limb ischemia
requiring surgical treatment and infection at the cannulation
site requiring surgical intervention were considered as
complications.
Statistics
Normal distributed variables were summarized as mean values
and standard deviation (SD), whereas skewed variables were
presented as median (interquartile range [IQR]). Categorical
data were summarized as frequency counts and percentages.
Continuous variables were compared using the unpaired t test
for normal distributed variables and the nonparametric Mann-
Whitney U-test for nonnormally distributed variables. Catego-
rical variables were compared with a Pearson w2 test of
independence. Overall survivals (OS) were presented using
Kaplan-Meier survival curves, and differences between BMI
groups were compared to the nonparametric log-rank test. All
tests were 2-sided, and values of P < .05 indicated a significant
difference. All analyses were performed using R (version
3.3.3).
Results
Patient Groups
A total of 928 patients had received percutaneous cannulation
for extracorporeal membrane oxygenation. Among those, 115
obese patients were supported with VV ECMO for acute
respiratory failure, and 38 obese patients were supported with
venoarterial ECMO (VA ECMO) after cardiogenic shock or
resuscitation. The latter group included 5 patients with severe
hypercapnia who had undergone arteriovenous extracorporeal
carbon dioxide removal (AV ECCO2R). The AV ECCO2R
patients were included in the VA ECMO group because they
had also required arterial and venous cannula insertion.
Demographic Data
Severe or morbid obesity was found in 153 (16.5%) of 928
patients with either isolated pulmonary or combined cardiopul-
monary failure who had received cannulation for extracorpor-
eal life support systems. The 38 obese patients (27 men and 11
women) who had received a VA ECMO because of cardiogenic
shock and/or resuscitation had a mean age of 56.8+ 9.8 years
and a mean BMI of 42.3+ 12.4 kg/m2 (range: 35-69.2 kg/m2).
A VV ECMO had been placed in 115 patients (76 men and 39
women) who had a mean age of 53.8+ 12.4 years and a mean
BMI of 43.9+ 10.1 kg/m2 (range: 35-84.5 kg/m2). The obese
VV ECMO patients were significantly older than the normal-
weight patients (53.83+ 12.35 vs 48.42+ 17.5, P < .05) and
had more often been referred to our center from a noncardio-
surgical center (62 [54%] vs 197 [43%], P < .05). The sequen-
tial organ failure assessment (SOFA) score appeared to be
comparable between severely or morbidly obese patients and
normal-weight patients in both the VV and the VA ECMO
group (VV ECMO 12.32 + 3.22 vs 11.35 + 3.94, P > .05,
VA ECMO 13.09+ 2.98 vs 11.82+ 3.15, P < .05).
However, renal failure prior to VA ECMO support was
apparent in 15 (39%) obese patients when compared to 50
(16%) normal-weight patients, which had statistical relevance
(P < .05). Multiple organ failure was seen in 23 (61%) obese
patients when compared to 129 (42%) normal-weight patients.
This finding was also statistically significant (P < .05). In the
VV ECMO group, multiple organ failure was observed in 56
(49%) obese patients and in 183 (40%) normal-weight patients
(P < .05). Demographic data are shown in Table 1 for VA
ECMO patients and in Table 2 for VV ECMO patients.
Cannulation
Cannulation was successfully performed in all 153 patients. In
the VA ECMO group, the return cannula could always be
implanted into a femoral artery. Drainage cannula access was
gained via the femoral vein in 34 patients and via the jugular
vein in 4 patients. A VA ECMO was placed in a referral hos-
pital in 12 patients, and 2 VA ECMOs were implanted by our
mobile ECMO team during extended cardiopulmonary resus-
citation outside a hospital. Obese patients had more often
received a jugular vein access than a femoral access for return
cannula than normal-weight patients (P < .05).
A femoro-jugular access was chosen in 70 (60.9%) obese
VV ECMO patients, a femoro-femoral access in 7 (6.1%), and
a femoro-subclavian access in 12 (10.4%) patients. In the latter
group, the subclavian vein served as a return vessel (see Table
3).Decannulation was event free without any surgical standby.
In 26 (22.6%) patients, the dual lumen catheter technique via
the jugular vein (Avalon cannula) was applied. Obese patients
were more often treated with the Avalon cannula than normal-
weight patients (26 [23%] patients vs 62 [14%] patients, P <
.05), that is, the jugular access was used more often in obese
patients (P < .05).
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It is noteworthy that 61 (53%) of the patients had the VV
ECMO implanted by our mobile ECMO team in another insti-
tute and were afterward transferred to our hospital by helicop-
ter or ambulance (Table 2).
Support and Complications
Median support interval was 5 days (IQR: 2-7, range: 0-20
days) in the VA ECMO group and 9 days (IQR: 6-14, range:
0-63 days) in the VV ECMO group. No statistical difference to
normal-weight patients could be found, neither in the VA
ECMO support (3 days; IQR: 1.75-6, range: 0-85 days) nor
in the VV ECMO group (8 days; IQR: 5-14, range: 0-94 days,
P > .05). Twenty (52%) obese patients treated with VA
ECMO—as well as all obese patients treated with AV
ECCO2R—were successfully weaned from the system. Six
patients died during follow-up, that is, overall 14 (37%)
patients survived and could be discharged from hospital. Wean-
ing was successful in 85 of the obese patients treated with VV
ECMO (74%), of whom 76 (66%) patients survived and could
be discharged from the hospital.
No significant difference in OS was found between severely
and morbidly obese VV or VA ECMO patients and normal-
weight patients (P > .05; see Figures 2 and 3).
Inappropriate cannulation such as malposition and disloca-
tion required relocation of the return cannula in 4 (10%) obese
patients supported with VA ECMO and in 6 (5%) patients
supported with VV ECMO. In normal-weight patients, reloca-
tion of the return cannula was necessary in 41 (13%) patients
supported with VA ECMO and in 15 (3%) patients supported
with VV ECMO. No statistically significant difference could
be found between obese and normal-weight patients in either
ECMO group. When compared to normal-weight patients,
severely or morbidly obese patients had significantly
more often thrombotic occlusions of the VV ECMO system
(48 [42%] obese patients and 130 [28%] normal-weight
patients, P < .05).
Obese patients had a similar risk of requiring transfusion of
packed red blood cells than normal-weight patients (0; IQR:
0-2, range: 0-14 vs 0 and IQR: 0-4; range: 0-35, P > .05). Also,
obese patients did not require more thrombocyte concentrates
than normal-weight patients (0; IQR: 0-0, range: 0-4 vs 0; IQR:
0-0, range: 0-13, P > .05). No differences in weaning, survival,
Table 1. Demographic data of patients supported with VA ECMO.
VA ECMO
Variable BMI > 35 kg/m2 BMI < 35 kg/m2
P
Value
Age, years 56.84 + 9.82 56.00+ 14.46 >.05
Gender
Male 27 (71%) 233 (74%) >.05
Female 11 (29%) 83 (26%)
Height, cm 170.63 + 14.60 172.13+ 7.20 >.05
Weight, kg 120.71 + 24.97 77.96+ 12.22 <.05
BMI 42.29 + 12.44 26.25+ 3.31 <.05
Resuscitation prior to
support
Yes 29 (76%) 263 (83%) >.05
No 9 (24%) 53 (17%)
Mode of resuscitation
None 9 (24%) 56 (18%) >.05
Mediction only 2 (5%) 29 (9%)
Mechanical 24 (63%) 199 (63%)
Mechanical assisted
(LUKAS)
3 (8%) 32 (10%)
Referral
Own hospital 19 (50%) 155 (49%) >.05
Distant
noncardiosurgical
hospital
17 (45%) 142 (45%)
Out of hospital 2 (5%) 19 (6%)
ECMO transportation
None 24 (63%) 192 (61%) >.05
Ambulance car 10 (26%) 57 (18%)
Helicopter 4 (11%) 67 (21%)
SOFA score 13.09 + 2.98 11.82+ 3.15 >.05
Abbreviations: SOFA, sequential organ failure assessment; VV ECMO, venove-
nous extracorporeal membrane oxygenation; BMI; body mass index.
Table 2. Demographic data of patients supported with VV ECMO.
VV ECMO
Variable BMI > 35 kg/m2 BMI < 35 kg/m2 P Value
Age, years 53.83 + 12.35 48.42+ 17.50 <.05
Gender
Male 76 (66%) 315 (69%) >.05
Female 39 (34%) 144 (31%)
Height, cm 170.74 + 7.29 171.10+ 14.79 >.05
Weight, kg 127.50 + 26.98 78.45+ 16.50 <.05
BMI 43.92 + 10.15 26.42+ 4.10 <.05
Resuscitation prior to
support
Yes 93 (81%) 382 (83%) >.05
No 22 (19%) 77 (17%)
Mode of resuscitation
None 103 (90%) 402 (88%) >.05
Medication only 11 (10%) 49 (11%)
Mechanical 1 (1%) 8 (2%)
Mechanical assisted
(LUKAS)
Referral
Own hospital 53 (46%) 262 (57%) <.05
Distant
noncardiosurgical
hospital
62 (54%) 197 (43%)
Out of hospital
ECMO transportation
None 54 (47%) 261 (57%) <.05
Ambulance car 26 (23%) 62 (14%)
Helicopter 35 (30%) 136 (30%)
SOFA score 12.32 + 3.22 11.35+ 3.94 >.05
Abbreviations: SOFA, sequential organ failure assessment; VV ECMO, venove-
nous extracorporeal membrane oxygenation; BMI; body mass index.
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Table 3. Cannulation.
VV ECMO VA ECMO
Variable BMI < 35 kg/m2 BMI > 35 kg/m2 P Value BMI < 35 kg/m2 BMI > 35 kg/m2 P Value
Mode of cannulation
Puncture and Seldinger technique 447 (97%) 113 (98%) >.05 250 (79%) 33 (87%) >.05
Seldinger technique via pre-existing access* 12 (3%) 2 (2%) 66 (21%) 5 (13%)
Drainage vessel
Femoral vein 385 (84%) 82 (71%) <.05 307 (97%) 34 (89%) <.05
Jugular vein 74 (16%) 33 (29%) 9 (3%) 4 (11%)
Return vessel
Jugular vein 412 (90%) 103 (90%) >.05
Subclavian vein 47 (10%) 12 (10%)
Femoral artery 316 (100%) 58 (100%)
Distal perfusion of limb
Yes 97 (31%) 9 (24%) >.05
No 219 (69%) 29 (76%)
Classic VV or Avalon
Classic VV 397 (86%) 89 (77%) <.05
Avalon 62 (14%) 26 (23%)
Abbreviations: BMI, body mass index; VV ECMO, venovenous extracorporeal membrane oxygenation; VA ECMO, venoarterial extracorporeal membrane
oxygenation.
*arterial line or intra-aortic blood pump.
Figure 2. Long-term follow-up of VV ECMO patients. Overall survival curves for patients treated with venovenous extracorporeal life-support
(VV ECMO) based on Kaplan-Meier produc. BMI indicates body mass index.
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cause of death, technical problems, and complications were
found between obese and normal-weight patients.
Due to bleeding, 6 (5%) patients required a blood transfu-
sion during implantation of VV ECMO, and 1 (3%) obese
patient in the VA ECMO group required surgical revision due
to bleeding at the cannulation site. Bleeding at the cannulation
site occurred in 31 (10%) normal-weight patients in the VA
ECMO group and in 21 (6%) patients in the VV ECMO group.
No significant difference in normal-weight patients was found
(P > .05).
Surgical intervention for limb ischemia was required in 5
(3%) obese patients including 1 patient of the VV ECMO
group. Limb ischemia was observed in 44 (14%) normal-
weight patients on VA ECMO support and in 21 (7%) patients
after decannulation. In the VV ECMO group, 4 (1%) normal-
weight patients had developed limb ischemia due to bleeding
at the cannulation site and compression of the adjacent
femoral artery.
Infection of the cannulation site was observed in 3 (2%)
obese patients and 5 (1%) normal-weight patients. All patients
were treated conservatively. No statistically significant differ-
ence has been found between obese and normal-weight patients
concerning limb ischemia or infection (both P > .05).
Discussion
As a result of numerous improvements in experience and tech-
nology, extracorporeal life support has become a widely
accepted device.1 By now, the implantation numbers of extra-
corporeal life-support systems have increased, and hardly any
obstacles exist neither with regard to the place of device
implantation nor the duration of support.4 However, in severe
obese patients, the cannulation procedure can be challenging.
Apart from obvious cannulation obstacles, the risk of compli-
cations is immanent. Therefore, appropriate patient selection, a
highly skilled team, and a sufficient training program are
important to avoid severe complications.
The range of obesity in both our ECMO groups is distinct.
The cutoff of the BMI of 35 kg/m2 was chosen according to the
definition of Sturm.5 A further splitting of patients was not
considered sensible with respect to the well-known fact that
the BMI is not necessarily a negative predictor for outcome in
patients with critical illness.6,7 Similarly, such patients should
not be denied extracorporeal life-support systems because of
their BMI as peripheral cannulation is easy to conduct.3 More-
over, such supposedly difficult cannulations may also be easily
accomplished outside a center providing the ECMO program.
Interestingly, inappropriate cannulation was rarely observed in
Figure 3. Long-term follow-up of VA ECMO patients. Overall survival curves for patients treated with venoarterial extracorporeal life-support
(VA ECMO) based on Kaplan-Meier product. BMI indicates body mass index.
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our group of severely and morbidly obese patients, of whom
only 4 patients treated with VA ECMO and 6 patients treated
with VV ECMO had required relocation of the cannula to the
opposite site. Generally, obese patients received a jugular vein
access more often than a femoral access compared to normal-
weight patients because the insertion of a venous drainage for
VA ECMO or an AVALON cannula in VV ECMO seems to be
easier in obese patients.
Obese patients treated with VV ECMO were significantly
older than normal-weight patients treated with VV ECMO.
Furthermore, obese patients were more often referred to our
center from hospitals without a VV ECMO program than
normal-weight patients. Nevertheless, we did not find any dif-
ference in the outcome between VA and VV ECMO. These
finding shows that extracorporeal life-support systems may be
used literally anywhere and that outcome is closely related to
selecting and managing the appropriate support tool.1
Patient outcome is influenced by underlying disease. The
best survival rates have been achieved in patients with less
comorbidities. Risk factors negatively affecting survival were
advanced age as well as renal and multiple organ failure.8 In
our experience, the SOFA score appears to be comparable
between severely or morbidly obese and normal-weight
patients. Obese patients not only seem to have a history of renal
failure more often than normal-weight patients but also have a
significantly higher risk of multiple organ failure. In spite of
higher incidences of comorbidities, obese and critically ill
patients tend to have a markedly high survival benefit.9 In
contrast to the study by Abhyankar et al, the present study on
ECMO did not yield any difference in the outcome and follow-
up between severely or morbidly obese and normal-weight
patients. Swol et al analyzed the relationship between BMI and
outcome of 89 surgical patients supported with VV ECMO.
Forty-five patients had a BMI of >30 kg/m2. Although a cutoff
BMI of 30.66 kg/m2 corresponded to the desired sensitivity and
specificity to predict mortality, the authors admitted that the
BMI had a poor decision-making power concerning ECMO
support.10 A comparable outcome of patients supported by
VV ECMOwas also published by Kon et al. Their retrospective
review study of 18 obese patients with a BMI of >40 kg/m2 in
comparison to 43 normal-weight patients showed a similar
outcome as well as comparable preexisting comorbidities of
patients requiring VV ECMO for acute respiratory distress
syndrome.11 Our study did not focus on comorbidities present
prior to ECMO support. We assumed a heterogeneous group of
patients because a substantial number of patients had been
referred to our center. Nevertheless, the outcome for obese
patients was not worse than that for normal-weight patients.
Obese and normal-weight patients in the VV and VA ECMO
groups showed comparable mean support times. We did not
find a significant difference in the average time of ECMO
support in comparison to the ELSO register (register of the
Extracorporeal Life-Support Organization).12 About 50% of
the patients supported with VA ECMO, roughly 75% of the
patients supported with VV ECMO, and all patients supported
with AV ECCO2R could successfully be weaned. These results
were consistent with the ELSO register as well.12
Overweight patients tended to need more heparin to achieve
the target PTT of 50 to 60 seconds. Nevertheless, obese patients
were more likely to experience clotting of the VV ECMO
system than normal-weight patients. The association between
obesity and thrombosis is well known. Elevated expression of
the prothrombotic molecules and increased platelet activation
are substantial parts of the pathomechanism.13,14 Furthermore,
there is a link between inflammation and thrombogenicity.15 It
is noteworthy that a statistically significant difference in throm-
bogenecity was found in VV ECMO patients but not in VA
ECMO patients. Thrombogenecity in ECMO featuring artifi-
cial surfaces remains the subject of further investigation.
The 2 most frequent complications of ECMO are bleeding
and infection at the cannulation site. In our study, bleeding
requiring the transfusion of packed red blood cells was rare
and comparable between severely or morbidly obese and
normal-weight patients. The incidence of bleeding was low for
VV and VA ECMO patients. Overall, we observed only one
infection at the cannulation site after surgical explantation of
the VV ECMO. The rate of our complications was comparable
with that of the ELSO registry.12 Therefore, we decannulate by
simply pulling out the cannulas.
Another major complication of ECMO systems is associated
limb ischemia due to cannulation. An incidence of 13% to 20%
has been reported with up to 50% of patients requiring fasciot-
omy.1,12,16-18 The patient cohort of our study had a remarkably
low incidence of limb ischemia that was even lower than that
reported in the literature.1 Distal limb perfusion, an essential
component of VA ECMO support, may substantially contribute
to reducing limb ischemia.
Our study has several limitations. It was designed as a retro-
spective study and conducted at one single medical center.
There may be selection bias as to who has been supported by
ECMO, therefore limiting the generalization of the findings.
Furthermore, the etiology of the patients’ diseases and the dif-
ferent conditions leading to the indication for ECMO support
were neither specified nor compared, which may have influ-
enced outcome and survival. Nevertheless, this study presents a
reasonable number of patients supported with either VV or VA
ECMO.Many of the patients had been transferred to our center.
The follow-up data present the long-term outcome of patients
supported by ECMO.
Conclusion
It is challenging but feasible to cannulate overweight patients
when conducted by experienced physicians, even out of hospi-
tal or at referral hospitals. The outcome of patients with cardi-
orespiratory impairment rather depends on the choice of the
appropriate support device and its implementation than on the
anatomy of the patient. Obesity should not be considered a
contraindication for VV ECMO or VA ECMO support.
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